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 RNA interference has been explored 
as a means of altering the phenotype 
of cells to gain insight into disease mecha-
nisms. 1 The paper by Thomaidis and 
colleagues 2 (this issue) describes the 
application of RNA interference to exam-
ine the cellular changes associated with 
silencing of the   -galactosidase A (AGAL) 
gene. 
 De$ cient AGAL activity is the cause of 
Anderson – Fabry disease (AFD), an 
inborn error of glycosphingolipid 
metabolism associated with abnormal 
accumulation of globotriaosylceramide 
(Gb3 / CD77) in multiple cell types. 3 AFD 
is an X-linked disorder; in the majority of 
affected males it is characterized by 
acroparesthesia with onset in childhood, 
and development of major morbidity from 
renal, cardiac, and central nervous system 
involvement in adulthood. 4 Although 
most females exhibit residual enzyme 
activity, a significant proportion may 
experience disease-related complications. 4 
Di3 erences in clinical expression among 
female carriers are partly attributable to 
lyonization, the phenomenon of random 
X-inactivation; but other modi$ ers, which 
are unknown at this point, are likely 
involved. 
 The major features of AFD, such as 
cardiomyopathy and renal insu4  ciency, 
are a re5 ection of the principal organ dis-
tribution of Gb3 deposits. Postmortem 
examination of a single male patient 
(age 44) revealed Gb3 accumulation in 
the heart and kidneys, corresponding to 
81.4 and 63.7 times the concentration 
found in an age- and sex-matched control 
sample. 5 Although intralysosomal sub-
strate storage is the most apparent patho-
logic finding, the molecular pathways 
leading to subsequent tissue damage and 
organ dysfunction in AFD are not fully 
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 Thomaidis and colleagues have created a cellular model of Anderson –
 Fabry disease by  ‘ silencing ’   -galactosidase A (AGAL) activity in human 
tubular epithelial cells. Increased membrane globotriaosylceramide 
(Gb3 / CD77) expression was observed; it is suggested that this finding 
may be potentially useful as a surrogate marker of disease severity. 
Decreased membrane Gb3 / CD77 expression was observed following 
agalsidase-  treatment, providing evidence of changes in cellular 
phenotype in response to enzyme therapy. 
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understood. Plasma or urinary Gb3 
levels in both hemizygous males and 
heterozygous females have not been 
shown to correlate consistently with 
disease severity; 6,7 this may be related 
to the possibility that Gb3 turnover in 
body 5 uids may not re5 ect the systemic 
tissue substrate burden. Recently, mark-
edly increased concentrations of dea-
cylated Gb3 (lyso-Gb3) have been found 
in the plasma of symptomatic AFD 
patients;  in vitro lyso-Gb3 has been shown 
to promote Gb3 storage (by inhibiting 
AGAL activity) and induce the prolifera-
tion of smooth muscle cells. 8 ; ese $ nd-
ings suggest a potentially greater role for 
lyso-Gb3 than for Gb3 in the pathogenesis 
of AFD, although details relating to down-
stream molecular events need to be fur-
ther characterized. 
 Studies in a murine model of AFD, 
generated by gene targeting and com-
plete knockout of AGAL activity, have 
revealed the presence of concentric lamel-
lar inclusions in the kidneys. 9 Although 
lipid analysis showed marked accumula-
tion of Gb3 in kidneys, a3 ected mice were 
clinically normal at 10 weeks of age. 9 Pro-
gressive tissue Gb3 deposits were found 
with increasing age, although clinical 
signs of AFD were not apparent in the 
a3 ected mouse, and organ failure was not 
detected up to 80 weeks of age. 10 To a cer-
tain extent, these observations may re5 ect 
species-speci$ c di3 erences: mouse eryth-
rocytes do not normally contain signi$ cant 
amounts of globoside and Gb3, and mice 
with complete absence of AGAL activity 
do not have apparent endothelial 
lesions. 10 
 Investigations have suggested a putative 
role for endothelial dysfunction in AFD, 
with evidence of abnormal vascular reac-
tivity, and increased propensity for throm-
bosis and atherogenesis. 11 – 13 A recent 
report highlights the complexity of the 
vasculopathy in AFD; studies in the 
murine model suggest there is an impair-
ment of endothelial cell – plasma mem-
brane receptor signaling. 14 Gb3 and other 
globo-series glycosphingolipids have 
been found in higher concentrations 
in caveolae of endothelial cells from 
a3 ected mice; 15 these changes may cause 
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5 uorescence would be increased in males, 
with a bimodal distribution in females 
depending on lyonization and Gb3 stor-
age. As the results shown were for the 
study subjects as a group, this point could 
not be clari$ ed. 
 Additional studies involved the treat-
ment of  ‘ silenced ’ HK2 cells with agalsi-
dase-  , a formulation of AGAL generated 
by gene activation in a human cell line; the 
results were consistent with a decrease in 
Gb3 / CD77 membrane expression to levels 
almost similar to those in untreated (non-
silenced) cells. 2 ; is observation provides 
additional proof of the concept that 
directed treatments, such as enzyme 
replacement therapy, address changes that 
represent the primary insult to cells (that 
is, substrate storage). 
 On $ nal analysis, the use of membrane 
Gb3 / CD77 expression as a surrogate 
marker of disease severity needs to be fur-
ther examined, through studies aimed at 
de$ ning the correlation between Gb3 /
 CD77 levels in relevant cell types and the 
pattern of clinical expression. ; e value of 
serial monitoring of Gb3 / CD77 expres-
sion in peripheral blood mononuclear 
cells also needs to be explored further, by 
looking at the pattern of its changes in 
relation to disease progression or thera-
peutic outcome. Besides the changes in 
Gb3 / CD77 expression in response to 
enzyme therapy, it would be of great inter-
est to know the corresponding e3 ects of 
investigational therapeutic approaches, 
such as substrate synthesis inhibition and 
chaperone-mediated enzyme enhance-
ment. ; e generation of a cellular model 
of AFD provides investigators with a 
means to identify mechanisms of disease 
and may lead to recognition of additional 
targets for treatment. 
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interference in receptor coupling with 
downstream mediators, which remain to 
be identi$ ed. Membrane Gb3 / CD77 acts 
as the receptor for most Shiga toxins, 
including verotoxin-1, an enterotoxin of 
enterohemorrhagic  Escherichia coli , which 
can induce acute renal failure. 16 Interest-
ingly, Gb3-de$ cient mice were found to 
be insensitive to otherwise lethal doses of 
verotoxin-1. 16 ; us, alteration in mem-
brane Gb3 content may serve as a point 
of entry, leading to convergent disease 
mechanisms associated with acquired and 
inherited disorders that end in renal 
failure — in which case, AFD may be 
viewed as another example of how inves-
tigations into rare diseases, nature ’ s so-
called  ‘ experiments, ’ can help elucidate 
pathophysiologic pathways that may have 
broad implications. 
 Thomaidis and colleagues 2 have 
pursued a di3 erent approach to get to 
the root of the problem in AFD. ; eir 
studies showed that inhibition of 
AGAL expression in human tubular epi-
thelial cells (HK2) and primary cultured 
tubular epithelial cells (TEC) led to the 
formation of osmiophilic intracellular 
inclusions resembling myelin $ gures, a 
characteristic finding in cells of AFD 
patients. 2 By 5 ow cytometric analysis, 
 ‘ silenced ’ cells were shown to have 
increased intracellular Gb3 expression, 
which was associated with increased 
Gb3 / CD77 membrane expression. 2 ; e 
latter is likely due to the metabolic logjam 
in substrate tra4  cking, which occurs as a 
consequence of progressive lysosomal 
Gb3 storage in cells with AGAL defi-
ciency. In Gaucher ’ s disease (glucocere-
brosidase deficiency), another inborn 
error of glycosphingolipid metabolism, 
analysis has revealed alteration in the 
lipid composition of microdomains. 17 
Conceivably, these changes may lead to a 
disruption of normal cellular signaling 
events. 
 Interestingly, the proportion of Gb3 /
 CD77-positive cells was di3 erent between 
cell types (greater in  ‘ silenced ’ HK2 cells 
than in TEC); this $ nding may re5 ect dif-
ferences in cell type-speci$ c transduction 
e4  ciency or AGAL expression, but this 
issue was not specifically examined. 
Quantitative biochemical analysis of the 
cellular lipid pro$ le would have been help-
ful validation of the model but was not 
performed. 
 Examination of the  ‘ silenced ’ cells using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
viability assay revealed signi$ cant reduc-
tion in comparison with control cells, 
which could be due to reduced prolifera-
tion and / or increased cell death. This 
observation should be followed up, to 
tease out its relevance to the pathophysiol-
ogy of AFD. It has been suggested that 
renal accumulation of Gb3 results in dis-
ease manifestations by a combination of 
vascular insu4  ciency, podocyte toxicity, 
and focal tubular damage and sclerosis; 18 
however, the molecular mechanisms 
underlying these putative changes have 
not been elucidated. The model of 
; omaidis  et al . 2 provides an opportunity 
to examine markers of apoptosis, 
proliferation, and other signaling mecha-
nisms involved in the renal pathology 
of AFD. 
 By transfection of speci$ c vectors into 
HK2 and tubular or glomerular epithelial 
cells, stable silencing of AGAL expression 
was induced, leading to the establishment 
of a cellular model for AFD. To authenti-
cate their $ ndings, the authors used 5 ow 
cytometric analysis to examine Gb3 / CD77 
expression in peripheral blood mononu-
clear cells isolated from male and female 
patients with AFD. CD77 was initially rec-
ognized as a B-cell antigen expressed on 
germinal center B cells and Burkitt ’ s lym-
phoma cells and was later found to be 
de$ ned by the Gb3 molecule. 19 It is of 
interest that ligation of carbohydrate moi-
ety of Gb3 / CD77 induces cell death in 
Gb3 / CD77-positive Burkitt ’ s lymphoma 
cells, not only by inhibiting protein syn-
thesis but also through apoptosis. 20 ; o-
maidis  et al . found that Gb3 / CD77 
expression was increased in a proportion 
of cells, with notable di3 erences in the size 
of the populations between controls and 
AFD patients. 2 Interestingly, the propor-
tion of Gb3 / CD77-positive cells from 
a3 ected individuals was small ( ~ 8 % ), but 
it is unclear whether this represents a dis-
crete and identi$ able cell population. Fur-
ther analysis of Gb3 / CD77, including 
mean cell 5 uorescence according to leu-
kocyte subset, would have been informa-
tive. It might be anticipated that mean cell 
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 Many parenchymal renal diseases charac-
terized by podocyte injury result from the 
interaction of genetic and environmental 
factors. 1 Collapsing glomerulopathy (CG) 
is no exception. Since its first clinical-
pathologic descriptions almost three dec-
ades ago, two general clinical correlates 
suggesting causality for CG continue to be 
strengthened: its predilection for patients 
of African descent; and its occurrence in 
conditions — many environmentally 
derived — with preceding immune 
activation, particularly T-helper type 1 
(; 1)-polarizing disorders. 2 Experimental 
evidence that the genetic susceptibilities 
of the former may be unmasked by the 
latter is only now forthcoming. 
 In this vein, a new study by Chan  et al. 3 
(this issue) makes an exciting advance-
ment toward understanding genetic 
susceptibilities for CG. ; e success of their 
multistep approach starts historically with 
the oM en serendipitous outcomes of reverse 
genetics in mice. In the late 1980s, the labo-
ratories of Malcolm Martin and Abner Not-
kins at the US National Institutes of Health 
collaboratively used transgenic technology 
to create FVB / N-strain mice bearing subg-
enomic human immunode$ ciency virus-1 
(HIV-1) proviral transgenes in efforts 
toward a rodent model of AIDS. Although 
human AIDS-like immunode$ ciency was 
not observed in the many transgenic found-
ers produced, a few curiously and unexpect-
edly developed renal disease strikingly 
similar to CG in HIV-infected patients. 4 
 Using the FVB / N Tg26 line resulting 
from this early discovery, 4 forward 
genetic techniques were then employed to 
map genetic susceptibility loci for CG. 5 
Cross-breeding of FVB / N Tg26 mice 
with several di3 erent inbred strains of mice 
showed a considerable strain-dependent 
variation in the severity of CG in F 1 prog-
eny. To identify genetic susceptibility loci 
present in one such strain, CAST, a mouse 
genome-wide analysis of linkage to 
increased severity of CG, was performed 
on B 1 progeny from backcrossing of 
(FVB / N Tg26  × CAST)F 1 with FVB / N 
Tg26 mice. ; is mapped a genetic suscep-
tibility locus, termed  HIVAN1 , to CAST 
mouse chromosome 3A1 – A3. 
 Collapsing glomerulopathy: 
beyond serendipity 
in mouse genetics 
 Peter J.  Nelson 1 and  Leslie  A. Bruggeman 2 
 Clinical correlates suggest that collapsing glomerulopathy results from 
the pathogenic interaction between patients ’ intractable genetic 
susceptibilities and environmental insults. When the environmental 
insults include a virus that introduces its own pathogenic genes, the 
interactions become more complex. Chan  et al. combine reverse and 
forward genetic techniques in mice toward understanding this 
complexity with HIV and identify candidate genetic modifiers of 
collapsing glomerulopathy. 
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